Refine by
Hypoglycemia Articles & Analysis
23 news found
Confo Therapeutics today reported preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), with findings presented at ENDO 2026. The data support CFTX-2034 as a potential first-in-class PBH therapy and advance the program toward IND-enabling studies.CFTX-2034 is a long-acting, highly selective agonistic antibody designed ...
Confo Therapeutics today reported preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), with findings presented at ENDO 2026. The data support CFTX-2034 as a potential first-in-class PBH therapy and advance the program toward IND-enabling studies.CFTX-2034 is a long-acting, highly selective agonistic antibody designed ...
Longer time in the glycemic target range and reduced variability in blood glucose are associated with significant clinical benefits including lower risk of severe hypoglycemia and improved quality of life. About Diamyd Medical Diamyd Medical develops precision medicine therapies for type 1 diabetes. ...
Abstract and publication #92-OR entitled “Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies,” to be presented Saturday, June 4, 2022 at 1:45 p.m. ...
VX-880 is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. ...
When this error occurs it can artificially raise the patient’s blood glucose sample measurement which can lead to the patient being given insulin inappropriately, potentially resulting in hypoglycemia with potential serious consequences. GLUCOSAVE® is designed to provide a visual alert to staff during the blood sampling process to prompt them to check if a glucose ...
ByMedovate
“The insulin-treated type 2 diabetes patient population is most at risk for complications of insulin, including hypoglycemia and excessive weight gain, but yet we as clinicians have the fewest tools to effectively treat these individuals,” said Vivian Fonseca, M.D., assistant dean for clinical research and Tullis-Tulane alumni chair in diabetes at Tulane University ...
Other study objectives include further evaluation of the safety and tolerability of ZT-01 and evaluation of symptoms and other hormones related to hypoglycemia. Topline results are expected in the first quarter of 2022. ...
IsletRx comprises an expanded population of clinical grade pancreatic islet-like cluster (ILCs) cells, derived from human stem cells, that have the ability to secrete insulin when blood sugar is low and glucagon, a hormone secreted to prevent hypoglycemia, when blood sugar levels drop in response to varying sugar levels (glucose) in the blood. ...
A novel treatment to prevent hypoglycemia would be a welcome tool and indispensable safeguard for people living with ...
“In collaboration with clinical sites in the United States and Europe, we look forward to evaluating Revita DMR in a segment of the type 2 diabetes population who are most at risk for hypoglycemia, weight gain and other significant complications of insulin ...
This does not slow disease progression, and it brings side effects including hypoglycemia, weight gain, and other risks. Revita DMR may present an alternative that can help achieve glucose control while reducing or eliminating the need for insulin. ...
(“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has expanded the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”). ...
(“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has expanded the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”). ...
The study results will help define ZT-01’s safety profile and establish doses to be used in an additional planned Phase 1 study to show the effect on glucagon during hypoglycemia in T1D patients. Insulin-induced hypoglycemia is a frequent, unintended consequence of insulin therapy for people with T1D and other types of insulin-dependent diabetes. ...
The study results will help define ZT-01’s safety profile and establish doses to be used in an additional planned Phase 1 study to show the effect on glucagon during hypoglycemia in T1D patients. Insulin-induced hypoglycemia is a frequent, unintended consequence of insulin therapy for people with T1D and other types of insulin-dependent diabetes. ...
Hypoglycemia is a well-documented problem for people with diabetes taking insulin. Continuous glucose monitor (CGM) technologies are increasingly used by insulin users, and are believed to be of great support to patients in reacting to impending hypoglycemia by alerting the patient to falling glucose levels. Despite this benefit, CGM users have mixed feelings ...
Hypoglycemia is associated with significant morbidity and mortality, yet there are currently no available therapeutics to prevent the condition. ZT-01 has the potential to restore the body’s ability to recover from hypoglycemia, which could improve disease management and prevent dangerous hypoglycemic episodes, potentially reducing long-term complications. ...
Hypoglycemia is associated with significant morbidity and mortality, yet there are currently no available therapeutics to prevent the condition. ZT-01 has the potential to restore the body’s ability to recover from hypoglycemia, which could improve disease management and prevent dangerous hypoglycemic episodes, potentially reducing long-term complications. ...
At Locemia, he led the creation and development of Baqsimi®, a needle-free repurposed rescue treatment for severe hypoglycemia; the product was acquired by Eli Lilly in 2015. Prior to Locemia, Dr. ...